Dibenzo[B,F][1,4]Oxazepine

Dibenzo[B,F][1,4]Oxazepine

SCHEMBL123289

C1=Nc2ccccc2Oc2ccccc21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
TRPA1 O75762 13/20 1.00
MAPT P10636 3/20 0.56
HTT P42858 2/20 0.56
MEN1 O00255 2/20 0.56
KMT2A Q03164 2/20 0.56
LMNA P02545 2/20 0.41
MAPK1 P28482 2/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
CYP1A2 P05177 1/20 0.39
CYP2D6 P10635 1/20 0.39
HPGD P15428 1/20 0.39
ALOX15 P16050 1/20 0.39
HSD17B10 Q99714 1/20 0.39
KDM4E B2RXH2 1/20 0.38
ALDH1A1 P00352 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Dibenzo[B,F][1,4]Oxazepine SCHEMBL30601896 0.98 TRPA1 (0.96) TRPA1MAPTHTTMEN1KMT2A
SCHEMBL9274057 0.83 TRPA1 (0.70) TRPA1MAPTHTTMEN1KMT2A
SCHEMBL8381353 0.82 TRPA1 (0.68) TRPA1MAPTHTTMEN1KMT2A
SCHEMBL29893838 0.82 TRPA1 (0.68) TRPA1MAPTHTTMEN1KMT2A
SCHEMBL9341207 0.82 TRPA1 (0.68) TRPA1MAPTHTTMEN1KMT2A
SCHEMBL3526060 0.79 TRPA1 (0.65) TRPA1MAPTHTTMEN1KMT2A
SCHEMBL7702745 0.79 TRPA1 (0.65) TRPA1MAPTHTTMEN1KMT2A
SCHEMBL9057247 0.79 TRPA1 (0.66) TRPA1MAPTHTTMEN1KMT2A
SCHEMBL3521057 0.79 TRPA1 (0.65) TRPA1MAPTHTTMEN1KMT2A
SCHEMBL8133280 0.79 TRPA1 (0.65) TRPA1MAPTHTTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 218 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119701804-A Aerosol generating device utilizing air injection spraying and blowing principles and control method 中国人民解放军61699部队 2025-03-28 CN claimed
CN-117109371-A Anti-riot stimulant aerosol generating device 中国人民解放军61699部队 2023-11-24 CN claimed
CN-116925143-A Method for synthesizing dibenzo [ b, f ] [1,4] oxazepine phosphorus-containing derivative 江苏科技大学 2023-10-24 CN claimed
WO-2023093398-A1 SYNTHESIS METHOD OF OXAZEPINE DERIVATIVE 江苏科技大学 2023-06-01 WO claimed
CN-113912562-B Synthetic method of oxazepine derivative 江苏科技大学 2023-03-28 CN claimed
US-20140045850-A1 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE INC. (CA) 2014-02-13 US claimed
EP-2217588-A1 INHIBITORS OF HISTONE DEACETYLASE Methylgene, Inc. (CA) 2010-08-18 EP claimed
WO-2009055917-A1 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE INC. (CA) 2009-05-07 WO claimed
US-20070175923-A1 Defense spray with wind indicator MCEVOY MICHAEL 2007-08-02 US claimed
US-6103715-A COMPOUNDS THAT BIND TO THE DOPAMINE D4 RECEPTOR AND THEIR USE AS ANXIOLYTIC AGENTS, TREATMENT FOR SCHIZOPHRENIA, AND DRUG SCREENING; SIDE EFFECT REDUCTIOON ALLELIX BIOPHARMACEUTICALS INC. (CA) 2000-08-15 US claimed
US-5561127-A TREATING ANXIETY, SCHIZOPHRENIA ALLELIX BIOPHARMACEUTICALS, INC. (CA) 1996-10-01 US claimed
US-5538965-A TREATMENT OF PSYCHOLOGICAL DISORDERS SUCH AS SCHIZOPHRENIA AND ANXIETY ALLELIX BIOPHARMACEUTICALS INC. (CA) 1996-07-23 US claimed
WO-1996019479-A1 MUSCARINIC RECEPTOR LIGANDS ALLELIX BIOPHARMACEUTICALS INC. (US) 1996-06-27 WO claimed
WO-1996018630-A1 BICYCLIC NONANE AND DECANE COMPOUNDS HAVING DOPAMINE RECEPTOR AFFINITY ALLELIX BIOPHARMACEUTICALS INC. (CA) 1996-06-20 WO claimed
WO-1996018629-A1 5-HT2 RECEPTOR LIGANDS ALLELIX BIOPHARMACEUTICALS INC. (US) 1996-06-20 WO claimed
WO-1996018621-A1 ALKYL-SUBSTITUTED COMPOUNDS HAVING DOPAMINE RECEPTOR AFFINITY ALLELIX BIOPHARMACEUTICALS INC. (US) 1996-06-20 WO claimed
WO-1996018623-A1 BENZYL-SUBSTITUTED COMPOUNDS HAVING DOPAMINE RECEPTOR AFFINITY ALLELIX BIOPHARMACEUTICALS INC. (US) 1996-06-20 WO claimed
WO-1995017400-A1 N-HETEROBICYCLYL-PIPERAZINYL OR-PIPERADINYL TRICYCLIC DERIVATIVES USEFUL AS DOPAMINE RECEPTOR LIGANDS ALLELIX BIOPHARMACEUTICALS INC. (CA) 1995-06-29 WO claimed
US-4410508-A DIBENZ-/B,F/-1,4-OXAZEPINE, SODIUM LAURYL SUFATE, POLYOXYETHYLATED LAURYL ALCOHOL, GLYCEROL THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) 1983-10-18 US claimed
EP-0012385-A1 Dibenz(b,f)(1,4)oxazepine derivatives, process for their preparation and pharmaceutical compositions Chugai Seiyaku Kabushiki Kaisha (JP) 1980-06-25 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140045850-A1 INHIBITORS OF HISTONE DEACETYLASE HDAC1, HDAC11, HDAC3 TRPA1 4141/4885MAPT 2336/4885HTT 878/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.